US Congress Senate Bill 3466 (Prior Session Legislation)

---

Spectrum: Bipartisan Bill
Status: Introduced on March 12 2020 - 25% progression, died in committee
Action: 2020-03-12 - Read twice and referred to the Committee on Finance.
Pending: Senate Finance Committee
Text: Latest bill text (Introduced) [PDF]

Temporarily eliminates cost-sharing for biosimilar biological products for certain qualifying beneficiaries under Medicare medical services. Specifically, the bill eliminates cost-sharing for beneficiaries whose coverage under private health insurance, a federal program (other than Medicare), a Medicare supplemental policy, or Medicare Advantage does not already do so. The Centers for Medicare & Medicaid Services must establish a process for determining a beneficiary's eligibility and notifying Medicare Advantage organizations of such determinations. The bill's provisions apply to products that are furnished during the five-year period beginning on January 1, 2021, or the date on which the product is first marketed, whichever is later.

Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2020

Sen. Martha McSally [R-AZ]

Sen. Doug Jones [D-AL]

Date	Chamber	Action
2020-03-12	Senate	Read twice and referred to the Committee on Finance.

HB4597 (Related) 2019-10-02 - Referred to the Subcommittee on Health.

Type	Source
Summary	https://www.congress.gov/bill/116th-congress/senate-bill/3466/all-info
Text	https://www.congress.gov/116/bills/s3466/BILLS-116s3466is.pdf